Overview

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Status:
Active, not recruiting

Trial end date:
2033-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

Phase:

Phase 2

Details

Lead Sponsor:

The First People's Hospital of Changzhou

Treatments:

Apatinib